发明申请
- 专利标题： ANTI-FIBROTIC COMPOUNDS
-
申请号： PCT/US2018/016272申请日： 2018-01-31
-
公开(公告)号： WO2018144620A1公开(公告)日： 2018-08-09
- 发明人: MILLER, Thomas , PAPAIOANNOU, Nikolaos
- 申请人： SHIRE HUMAN GENETIC THERAPIES, INC.
- 申请人地址： 300 Shire Way Lexington, MA 02421 US
- 专利权人： SHIRE HUMAN GENETIC THERAPIES, INC.
- 当前专利权人： SHIRE HUMAN GENETIC THERAPIES, INC.
- 当前专利权人地址： 300 Shire Way Lexington, MA 02421 US
- 代理机构： DUFFEY, Matthew, O.
- 优先权： US62/454,358 20170203
- 主分类号： C07C235/38
- IPC分类号： C07C235/38 ; A61K31/167 ; A61P17/00 ; C07C235/40 ; C07C237/20 ; C07C255/60 ; C07D205/04 ; C07D207/12 ; C07D207/24 ; C07D209/46 ; C07D211/22 ; C07D211/26 ; C07D211/46 ; C07D211/58 ; C07D213/30
摘要：
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))
公开/授权文献
- WO2018144620A9 ANTI-FIBROTIC COMPOUNDS 公开/授权日：2018-08-09
